Navigation Links
Vantia Therapeutics Appoints Rachel Morten as Head of Regulatory Affairs
Date:4/21/2009

SOUTHAMPTON, England, April 21 /PRNewswire/ -- Vantia Therapeutics, a company developing novel small molecule drugs targeting large underserved medical markets, today announces the appointment of Rachel Morten as Head of Regulatory Affairs.

Rachel has more than 24 years experience in global regulatory affairs and product development in the pharmaceutical and animal health industries. Most recently an independent regulatory affairs consultant, Rachel has also served as Senior Director, Group Head Regulatory Affairs for the international CRO Averion International Ltd (previously Hesperion). Previously Rachel founded ChapelPharma a regulatory consultancy that was acquired by Hesperion in 2004.

Dr Jim Phillips, CEO of Vantia Therapeutics, said: "Rachel brings to Vantia years of experience across all regulatory aspects of the global development of new chemical entities from pre-clinical through to Phase III. She is an excellent addition to our already high-quality management team at Vantia and I look forward to working with her as our clinical and pre-clinical pipeline continues to mature."

Rachel Morten, Head of Regulatory Affairs, said: "Vantia has already made great progress with its pipeline, with the Phase IIa trial of VA106483 for nocturia recently completed and dosing complete in the Phase I trial of VA111913 for dysmenorrhoea. These products target conditions which affect millions of people and are poorly served by current treatments. It is the quality of these programmes, the pre-clinical pipeline and the drug discovery engine that made the opportunity of joining the team at Vantia so exciting."

Notes to Editors

About Vantia Therapeutics:

Vantia Therapeutics is an emerging pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical markets. Its rapidly advancing clinical pipeline includes VA106483 for nocturia
'/>"/>

SOURCE Vantia Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... 2014 One of the major revolutions taking ... which is the practice of using genomic and other ... individual biology. Personalized diagnostics—laboratory analyses that inform the practice ... lab,s future. This fall, AACC ,s first ever ... in this exciting field and the novel technologies driving ...
(Date:8/1/2014)... 1, 2014 According to a ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... at USD 25.16 billion in 2013, which is expected ... a CAGR of 10.4% from 2014 to 2020. ... Increasing demand for accurate early diagnosis ...
(Date:8/1/2014)... Once a decision has been made to ... discuss how to define your tolerance for lowest cost ... Senior Director of Facilities Integration at Fluor Industrial Services, ... Services, and special guest Carrier Li, Director in Global ... they provide an examination of the Conceptual Design process ...
(Date:8/1/2014)... 2014 Cambrex Corporation (NYSE: CBM ) ... Highlights , Second quarter sales ... same period last year. , Second quarter EBITDA increased ... same period last year (see table at the end of ... excluding the impact of foreign currency, to between 13% and ...
Breaking Biology Technology:First-Ever AACC Virtual Conference to Focus on Personalized Diagnostics 2Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 2Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 3Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 4Defining Low Cost in Your Solution for Future Facilities, New Webinar for Pharma, Biotech, Medical Device and Healthcare Companies, Hosted by Xtalks 2Cambrex Reports Second Quarter 2014 Financial Results 2Cambrex Reports Second Quarter 2014 Financial Results 3Cambrex Reports Second Quarter 2014 Financial Results 4Cambrex Reports Second Quarter 2014 Financial Results 5Cambrex Reports Second Quarter 2014 Financial Results 6Cambrex Reports Second Quarter 2014 Financial Results 7Cambrex Reports Second Quarter 2014 Financial Results 8Cambrex Reports Second Quarter 2014 Financial Results 9Cambrex Reports Second Quarter 2014 Financial Results 10Cambrex Reports Second Quarter 2014 Financial Results 11Cambrex Reports Second Quarter 2014 Financial Results 12Cambrex Reports Second Quarter 2014 Financial Results 13Cambrex Reports Second Quarter 2014 Financial Results 14Cambrex Reports Second Quarter 2014 Financial Results 15Cambrex Reports Second Quarter 2014 Financial Results 16
... 28 /PRNewswire-FirstCall/,-- Evotec AG (Frankfurt Stock Exchange: EVT) ... year ended December 31, 2007., Financial results ... in the,Company,s clinical pipeline and four major corporate ... Technologies (ET), the sale of,the Chemical Development Business ...
... CHAMPAIGN, Ill. Finding a simple and convenient ... identification has been an elusive goal. With current ... ratio too poor, sample preparation too complex or ... service., Now, researchers at the University of Illinois ...
... March 27 Local biotechnology leader,MedImmune announced ... Yiwei Li,has received the distinguished "MedImmune Advancing ... project. The company sponsored the,Montgomery County science ... and presented the award to recognize the ...
Cached Biology Technology:Evotec Announces Financial Results for 2007 2Evotec Announces Financial Results for 2007 3Evotec Announces Financial Results for 2007 4Evotec Announces Financial Results for 2007 5Evotec Announces Financial Results for 2007 6Evotec Announces Financial Results for 2007 7Evotec Announces Financial Results for 2007 8Femtogram-level chemical measurements now possible, U. of I. team reports 2Seneca Valley High School Student Receives Science Award From MedImmune 2Seneca Valley High School Student Receives Science Award From MedImmune 3
(Date:7/31/2014)... research, supported by the National Science Foundation (NSF), ... uniformly accelerates atmospheric warming, indicating instead that certain ... emit into the atmosphere. , The study, ... , focuses on thermokarst lakes, which occur as ... with melted fresh water, converting what was previously ...
(Date:7/31/2014)... long-term follow-up study (HPV-023; NCT00518336) shows the ... human papilloma virus (HPV) vaccine Cervarix. Women ... followed for more than nine years, and ... 100%. This is the longest follow-up report ... https://www.landesbioscience.com/journals/vaccines/article/29532/ for the full paper. , ...
(Date:7/31/2014)... of animal models against the highly infectious and virulent ... disease that kills approximately 30,000 Americans annually. The research ... Immunity . , In the study, the vaccine ... toxins produced by C. difficile , as well ... that mimics the human disease, after only two immunizations. ...
Breaking Biology News(10 mins):Certain Arctic lakes store more greenhouse gases than they release 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3C. difficile vaccine proves safe, 100 percent effective in animal models 2
... CHURCH, Va., Feb. 2 CSC (NYSE: ... 12 contractors awarded a Biometrics Operations and Support Services ... Biometrics Task Force (BTF). The indefinite-delivery/indefinite-quantity (IDIQ) contract covers ... to meet the mission needs of BTF business and ...
... 25 percent of eligible African-American adolescents have received the ... Association for Cancer Research conference on the Science of ... of the treatment and might respond to more education. ... funding research to develop ways to increase the rate ...
... University is tracking the movement of the Redbay Ambrosia beetle, ... may severely affect the production of avocados, a $15 million ... in the United States near Savannah, Ga., in 2002, the ... causing widespread mortality in Redbay trees. Dr. Frank Koch, a ...
Cached Biology News:CSC Awarded Department of Defense Biometrics Contract 2African-Americans aware and accepting, but often do not receive, the HPV vaccine 2Holy guacamole: invasive beetle threatens Florida's avocados 2
...
...
... are designed to rapidly and reliably amplify ... APA Technology. APAgene provides hassle-free, ready-to use ... necessary ingredients are provided in each kit. ... for gap filling, localized cloning of genomic ...
N,N'-Methylene-bis-acrylamide, Ultra Pure...
Biology Products: